These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 32553783)

  • 1. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
    Fang J; Islam W; Maeda H
    Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors.
    Islam R; Maeda H; Fang J
    Expert Opin Drug Deliv; 2022 Feb; 19(2):199-212. PubMed ID: 33430661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
    Maeda H; Wu J; Sawa T; Matsumura Y; Hori K
    J Control Release; 2000 Mar; 65(1-2):271-84. PubMed ID: 10699287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
    Maeda H; Tsukigawa K; Fang J
    Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
    Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
    Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
    Fang J; Sawa T; Maeda H
    Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
    Maeda H; Nakamura H; Fang J
    Adv Drug Deliv Rev; 2013 Jan; 65(1):71-9. PubMed ID: 23088862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
    Maeda H
    Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
    Maeda H
    Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(3):53-71. PubMed ID: 22450535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
    Fang J; Nakamura H; Maeda H
    Adv Drug Deliv Rev; 2011 Mar; 63(3):136-51. PubMed ID: 20441782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
    Maeda H
    Bioconjug Chem; 2010 May; 21(5):797-802. PubMed ID: 20397686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
    Nakamura H; Fang J; Maeda H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect.
    Maeda H
    Cancer Sci; 2013 Jul; 104(7):779-89. PubMed ID: 23495730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect.
    Islam W; Kimura S; Islam R; Harada A; Ono K; Fang J; Niidome T; Sawa T; Maeda H
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34071552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymer therapeutics and the EPR effect.
    Maeda H
    J Drug Target; 2017; 25(9-10):781-785. PubMed ID: 28988499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
    Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
    J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcytosis-enabled active extravasation of tumor nanomedicine.
    Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
    Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the enhanced permeability and retention effect for tumor targeting.
    Iyer AK; Khaled G; Fang J; Maeda H
    Drug Discov Today; 2006 Sep; 11(17-18):812-8. PubMed ID: 16935749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
    Natfji AA; Ravishankar D; Osborn HMI; Greco F
    J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.